Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04816630 · ClinicalTrials.gov registry record
Feasibility Study of Hematology Parameters in COVID-19 Disease
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 32
- Enrollment target
NCT04816630: Completed study, sponsored by Beckman Coulter.
NCT04816630 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04816630 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or respiratory infection and whose standard of care includes CBC-DIFF and microbial testing.
Primary Outcome
MDW's ability to identify COVID-19 negative versus COVID-19 positive patients using RT-PCR
Interventions
- DEVICE CBC-Diff Monocyte Volume Width Distribution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2021-09-22 |
What the finished NCT04816630 record still lists
NCT04816630 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CBC-Diff Monocyte Volume Width Distribution is the first listed.
NCT04816630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04816630 about?
NCT04816630 is a clinical study titled "Feasibility Study of Hematology Parameters in COVID-19 Disease". The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or respiratory infection and whose standard of care includes CBC-DIFF and m...
What is the current status of trial NCT04816630?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2020-12-21. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT04816630?
The interventions under investigation include: CBC-Diff Monocyte Volume Width Distribution (DEVICE).
Who is sponsoring clinical trial NCT04816630?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI